obesity treatment with bariatric surgery vs glp-1 receptor agonists The role of glucagon-like peptide-1 in weight regain or prevention after surgery: a systematic review and meta-analysis | Eating and Weight Disorders Bariatric Surgery Outperforms GLP-1s in
Description
Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis
GLP-1RAs improve hyperglycemia by enhancing insulin secretion through increases in -cell cytoplasmic cyclic adenosine monophosphate [53], which activates protein kinase A (PKA) and, thus, increases in intracellular calcium and triggers insulin exocytosis in a glucose-dependent manner [54]
Implications for employers: - Rebates and discounts are large for GLP-1 drugs for diabetes and obesity, and employers need to consider this when planning management programs and building future pharmacy budgets
doi: 10.1056/NEJMoa1411892 93 WaddenTAHollanderPKleinSNiswenderKWooVHalePMet al
What remains unclear is whether patients taking GLP-1 RAs have an increased risk of aspiration
Wu Z, McGoogan JM
